Bradley P. Knight
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bradley P. Knight has a total of 424 co-authors. Here are the top co-authors by number of shared publications:
- Jeremiah Wasserlauf
Division of Cardiology Endeavor Health System – NorthShore University Health System Glenbrook Illinois USA
10 shared publications - Graham Peigh
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
9 shared publications - Rod Passman
Division of Cardiology, Feinberg School of Medicine, Northwestern University , 676 N St Claire, Suite 600, Chicago, IL 60611
9 shared publications - Nishant Verma
Division of Cardiology Northwestern University Chicago Illinois USA
8 shared publications - Jaimie Manlucu
University of Western Ontario
7 shared publications - Rachel M. Kaplan
Division of Cardiology Medical University of South Carolina Charleston South Carolina USA
7 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in Heart Rhythm O2
Real-world performance and diagnostic yield gains of a next-generation patch-based 14-day uninterrupted ambulatory electrocardiogram monitor
- 9 October 2026
- Published by Elsevier in Heart Rhythm O2
Open AccessReal-world performance and diagnostic yield gains of a next-generation patch-based 14-day uninterrupted ambulatory electrocardiogram monitor
- Open Access
- 25 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Safety and efficacy of left atrial ablation after percutaneous left atrial appendage occlusion in high-bleeding-risk patients with atrial fibrillation: a multicentre analysis from the PROCEED-AF ablation registry
Aims: Patients with left atrial appendage (LAAO) devices are increasingly referred for atrial fibrillation (AF) ablation, yet anticoagulation strategies remain uncertain. The goal of this study was to evaluate the safety and efficacy of catheter ablation for AF in patients with pre-existing LAAO devices and to describe patterns in anticoagulation management after ablation in this unique population. Methods and results: We collected data from 14 centres worldwide on patients with prior LAAO devices undergoing AF ablation. Each site provided clinical characteristics, procedural details, and information on complications and arrhythmia outcomes. Data were aggregated and analysed centrally to evaluate procedural safety, efficacy, and variability in management strategies. A total of 198 patients (age 70 years, 37% female, 42% paroxysmal AF) with prior LAAO were included. Ablation was performed a median of 271 days after LAAO. After ablation, 84% of patients were on oral anticoagulation (OAC), most commonly for 2–3 months. Bleeding complications on OAC occurred in 6.7% of patients at a median of 20 (13, 70) days after ablation. Stroke or TIA occurred in five patients (2.6% of cases) within the follow-up period with two occurrences (1% of cases) the day after ablation. There were two cases of new or worsened peri-device leak after ablation. Conclusion: In a large, international registry of patients undergoing catheter ablation for AF with pre-existing LAAO devices, ablation was feasible, and device related complications were rare. Despite higher bleeding risk in an LAAO population, 84% of patients with prior LAAO tolerated short-term OAC post-ablation with bleeding events at expected rates for this population.
- 25 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Open AccessSafety and efficacy of left atrial ablation after percutaneous left atrial appendage occlusion in high-bleeding-risk patients with atrial fibrillation: a multicentre analysis from the PROCEED-AF ablation registry
Aims: Patients with left atrial appendage (LAAO) devices are increasingly referred for atrial fibrillation (AF) ablation, yet anticoagulation strategies remain uncertain. The goal of this study was to evaluate the safety and efficacy of catheter ablation for AF in patients with pre-existing LAAO devices and to describe patterns in anticoagulation management after ablation in this unique population. Methods and results: We collected data from 14 centres worldwide on patients with prior LAAO devices undergoing AF ablation. Each site provided clinical characteristics, procedural details, and information on complications and arrhythmia outcomes. Data were aggregated and analysed centrally to evaluate procedural safety, efficacy, and variability in management strategies. A total of 198 patients (age 70 years, 37% female, 42% paroxysmal AF) with prior LAAO were included. Ablation was performed a median of 271 days after LAAO. After ablation, 84% of patients were on oral anticoagulation (OAC), most commonly for 2–3 months. Bleeding complications on OAC occurred in 6.7% of patients at a median of 20 (13, 70) days after ablation. Stroke or TIA occurred in five patients (2.6% of cases) within the follow-up period with two occurrences (1% of cases) the day after ablation. There were two cases of new or worsened peri-device leak after ablation. Conclusion: In a large, international registry of patients undergoing catheter ablation for AF with pre-existing LAAO devices, ablation was feasible, and device related complications were rare. Despite higher bleeding risk in an LAAO population, 84% of patients with prior LAAO tolerated short-term OAC post-ablation with bleeding events at expected rates for this population.
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (9)
When Science Is Sidelined: Implications of US Vaccine Policy Rollbacks for Electrophysiology and Cardiovascular Health
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (9)
When Science Is Sidelined: Implications of US Vaccine Policy Rollbacks for Electrophysiology and Cardiovascular Health
- Open Access
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70457
Postoperative Atrial Arrhythmias After Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes
Background: Postoperative atrial arrhythmia (POAA) is common after lung transplant, but data on its implications and management are limited. This study assessed POAA incidence and timing, its association with mortality and rehospitalizations, and outcomes related to postoperative beta‐blocker use. Methods: We retrospectively studied 233 adult lung transplant patients at Northwestern Memorial Hospital (2014–2024) without prior atrial arrhythmia. POAA, defined as atrial fibrillation or flutter, was confirmed by ECG or ambulatory monitoring. Multivariable logistic and Cox regression models evaluated predictors and outcomes, adjusting for covariates. Results: POAA occurred in 69/233 patients (29.6%) and was associated with higher mortality (HR3.09, 95%CI [1.57–6.08]). Among these, 18/69 (26.1%) developed POAA after the index hospitalization at median 216 days post‐transplant, also associated with higher mortality (HR4.37, 95%CI [1.90–10.06]). Additionally, 10/69 (14.5%) required emergency visits or hospitalization specifically for arrhythmia management, and 66.6% underwent additional rhythm control (2.9% cardioversion, 46.4% anti‐arrhythmic drug, 17.4% both). Postoperative beta‐blocker use was associated with 73% less POAA (HR0.27, 95%CI [0.09–0.80]). Conclusion: POAA was common and clinically significant after lung transplant, associated with substantially higher adjusted mortality even when occurring after index hospitalization. We report for the first time that POAA was frequently associated with emergency visits or rehospitalization for arrhythmia, highlighting its clinical burden well beyond the perioperative period. Postoperative beta‐blocker use was associated with markedly less POAA, a novel finding suggesting a potential prophylactic role. Overall, these findings challenge the traditional view of POAA as benign and highlight the need for tailored, evidence‐based guidelines in this high‐risk population.
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70457
Open AccessPostoperative Atrial Arrhythmias After Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes
Background: Postoperative atrial arrhythmia (POAA) is common after lung transplant, but data on its implications and management are limited. This study assessed POAA incidence and timing, its association with mortality and rehospitalizations, and outcomes related to postoperative beta‐blocker use. Methods: We retrospectively studied 233 adult lung transplant patients at Northwestern Memorial Hospital (2014–2024) without prior atrial arrhythmia. POAA, defined as atrial fibrillation or flutter, was confirmed by ECG or ambulatory monitoring. Multivariable logistic and Cox regression models evaluated predictors and outcomes, adjusting for covariates. Results: POAA occurred in 69/233 patients (29.6%) and was associated with higher mortality (HR3.09, 95%CI [1.57–6.08]). Among these, 18/69 (26.1%) developed POAA after the index hospitalization at median 216 days post‐transplant, also associated with higher mortality (HR4.37, 95%CI [1.90–10.06]). Additionally, 10/69 (14.5%) required emergency visits or hospitalization specifically for arrhythmia management, and 66.6% underwent additional rhythm control (2.9% cardioversion, 46.4% anti‐arrhythmic drug, 17.4% both). Postoperative beta‐blocker use was associated with 73% less POAA (HR0.27, 95%CI [0.09–0.80]). Conclusion: POAA was common and clinically significant after lung transplant, associated with substantially higher adjusted mortality even when occurring after index hospitalization. We report for the first time that POAA was frequently associated with emergency visits or rehospitalization for arrhythmia, highlighting its clinical burden well beyond the perioperative period. Postoperative beta‐blocker use was associated with markedly less POAA, a novel finding suggesting a potential prophylactic role. Overall, these findings challenge the traditional view of POAA as benign and highlight the need for tailored, evidence‐based guidelines in this high‐risk population.
- Open Access
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (6) , e240554
Highly Accelerated Real-time Cine MRI Pulse Sequence for Cardiac Implantable Electronic Devices and Arrhythmias
A 32-fold accelerated real-time cine MRI sequence (radial sampling) demonstrated better temporal resolution and image quality than a 16-fold sequence (Cartesian sampling) in patients with cardiac implantable electronic devices and arrhythmias.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (6) , e240554
Open AccessHighly Accelerated Real-time Cine MRI Pulse Sequence for Cardiac Implantable Electronic Devices and Arrhythmias
A 32-fold accelerated real-time cine MRI sequence (radial sampling) demonstrated better temporal resolution and image quality than a 16-fold sequence (Cartesian sampling) in patients with cardiac implantable electronic devices and arrhythmias.
- Open Access
- 18 August 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
Catheter Ablation: Evolution and Efficiencies
The present review includes a discussion the goals and pitfalls of efficiency in the medical profession, a historical perspective on the evolution of catheter ablation in the field of electrophysiology (EP), and the data regarding the relationship between efficiency and outcomes in the EP lab. Focus on efficacy is critical to maximize resource utilization, avoiding complications, and optimizing patient care.
- 18 August 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
Open AccessCatheter Ablation: Evolution and Efficiencies
The present review includes a discussion the goals and pitfalls of efficiency in the medical profession, a historical perspective on the evolution of catheter ablation in the field of electrophysiology (EP), and the data regarding the relationship between efficiency and outcomes in the EP lab. Focus on efficacy is critical to maximize resource utilization, avoiding complications, and optimizing patient care.
- Open Access
Post-Operative Atrial Arrhythmias after Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes
Background: Following lung transplant, many patients develop post-operative atrial fibrillation (AF) or atrial flutter (AFL)–collectively defined as post-operative atrial arrhythmia (POAA). While early (in-hospital) POAA is linked to increased mortality, late (post-discharge) POAA is poorly understood. Risk factors and real-world management strategies for POAA are not well characterized. We aim to evaluate POAA incidence and timing, identify risk and protective factors, and assess associations with mortality and long-term outcomes. Methods: This retrospective cohort study included 233 adult lung transplant recipients at Northwestern Memorial Hospital (2014–2024), excluding those with pre-existing AF or AFL. POAA was confirmed by ECG or Holter. Adjusted logistic and Cox regressions identified predictors of POAA and mortality. Results: Of 233 recipients (age 58.6±12.8y, 45.1% female), POAA occurred in 29.6% (53.6% AF, 24.6% AFL, 21.7% both). Both overall (HR4.06, 95%CI[2.21–7.46]) and late (HR3.01, 95%CI[1.39–6.53]) POAA were significantly associated with mortality. 14.5% of patients with POAA required hospital-based arrhythmia management and 66.6% underwent additional rhythm control (2.9%% DCCV, 46.4% AAD initiation, 17.4% both). Preoperative pulmonary arterial hypertension (PAH) was associated with less POAA (OR0.31, 95%CI[0.14–0.62]). Postoperative beta-blocker use was associated with 73% reduced POAA (HR0.27, 95%CI[0.09–0.80]). Conclusions: This study is among the first to associate late POAA with mortality and define arrhythmia-related hospitalization rates after POAA. Postoperative beta-blockers were associated with significantly less POAA, a novel finding in lung transplant recipients. Finally, preoperative PAH’s association with less POAA might reflect reduced cardiac strain post-transplant.
Open AccessPost-Operative Atrial Arrhythmias after Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes
Background: Following lung transplant, many patients develop post-operative atrial fibrillation (AF) or atrial flutter (AFL)–collectively defined as post-operative atrial arrhythmia (POAA). While early (in-hospital) POAA is linked to increased mortality, late (post-discharge) POAA is poorly understood. Risk factors and real-world management strategies for POAA are not well characterized. We aim to evaluate POAA incidence and timing, identify risk and protective factors, and assess associations with mortality and long-term outcomes. Methods: This retrospective cohort study included 233 adult lung transplant recipients at Northwestern Memorial Hospital (2014–2024), excluding those with pre-existing AF or AFL. POAA was confirmed by ECG or Holter. Adjusted logistic and Cox regressions identified predictors of POAA and mortality. Results: Of 233 recipients (age 58.6±12.8y, 45.1% female), POAA occurred in 29.6% (53.6% AF, 24.6% AFL, 21.7% both). Both overall (HR4.06, 95%CI[2.21–7.46]) and late (HR3.01, 95%CI[1.39–6.53]) POAA were significantly associated with mortality. 14.5% of patients with POAA required hospital-based arrhythmia management and 66.6% underwent additional rhythm control (2.9%% DCCV, 46.4% AAD initiation, 17.4% both). Preoperative pulmonary arterial hypertension (PAH) was associated with less POAA (OR0.31, 95%CI[0.14–0.62]). Postoperative beta-blocker use was associated with 73% reduced POAA (HR0.27, 95%CI[0.09–0.80]). Conclusions: This study is among the first to associate late POAA with mortality and define arrhythmia-related hospitalization rates after POAA. Postoperative beta-blockers were associated with significantly less POAA, a novel finding in lung transplant recipients. Finally, preoperative PAH’s association with less POAA might reflect reduced cardiac strain post-transplant.
- Open Access
- 2 April 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (10) , 2767-2775
Implantable Defibrillators: Which Is the Best Device for Each Patient?
The first viable alternative to surgical implantation of an epicardial defibrillator system for secondary prevention of sudden cardiac death (SCD) was a single chamber transvenous implantable cardioverter defibrillator (ICD). Thanks to technological advancements over the past 40 years, electrophysiologists now have several options when determining the optimal type of ICD to provide protection against SCD, including the number of leads implanted, whether a patient meets indications for cardiac resynchronization, and if the patient would benefit from an extravascular device. In this review, we will detail the breadth of options for commercially available ICD therapy to provide guidance on which device is best suited for specific patient populations.
- 2 April 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (10) , 2767-2775
Open AccessImplantable Defibrillators: Which Is the Best Device for Each Patient?
The first viable alternative to surgical implantation of an epicardial defibrillator system for secondary prevention of sudden cardiac death (SCD) was a single chamber transvenous implantable cardioverter defibrillator (ICD). Thanks to technological advancements over the past 40 years, electrophysiologists now have several options when determining the optimal type of ICD to provide protection against SCD, including the number of leads implanted, whether a patient meets indications for cardiac resynchronization, and if the patient would benefit from an extravascular device. In this review, we will detail the breadth of options for commercially available ICD therapy to provide guidance on which device is best suited for specific patient populations.
- Open Access
- 13 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (6) , e037019
Multicenter Experience With a Novel Real‐Time 3‐Dimensional Intracardiac Echocardiography Catheter to Guide Interventional Cardiac Procedures
Background: Recent technologies enable real‐time 3‐dimensional intracardiac echocardiography (ICE) with the advantages of 2‐dimensional ICE and imaging capabilities of transesophageal echocardiography. The purpose of this study is to evaluate the real‐world, multicenter safety and performance of a novel 3‐dimensional ICE system in a variety of cardiac interventions used in standard clinical practice. Methods: This prospective, multicenter, observational, single‐arm study enrolled patients who were scheduled for an invasive cardiac procedure involving guidance with ICE and followed until discharge or ≤48 hours postprocedure. Intracardiac imaging was performed with the 3‐dimensional ICE catheter, VeriSight Pro (Philips Inc.). Fluoroscopy was used in all cases and transesophageal echocardiography was used in some cases. The primary safety end point was device‐related adverse events. The primary efficacy end point included technical success, imaging success, and clinical success. Results: Between October 2021 and November 2022, 155 patients were enrolled and screened. Percutaneous interventions performed included atrial septal defect/patent foramen ovale closures, left atrial appendage occlusion, catheter ablations, and valve procedures. No adverse events were related to the device or procedure. The technical, imaging, and clinical success rates were 98.7% (95% CI, 95.4%–99.8%), 96.1% (95% CI, 91.8%–98.6%), 94.8% (95% CI, 91.8%–98.6%), respectively. Overall, the VeriSight Pro ICE image quality was assessed to be “acceptable” or greater in relation to reference image modality among 96.2% (149 of 155) of procedures. Conclusions: VeriSight ICE imaging is safe and effective in the guidance of a wide variety of percutaneous cardiovascular procedures and has provided successful and high‐quality imaging of cardiac structures.
- 13 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (6) , e037019
Open AccessMulticenter Experience With a Novel Real‐Time 3‐Dimensional Intracardiac Echocardiography Catheter to Guide Interventional Cardiac Procedures
Background: Recent technologies enable real‐time 3‐dimensional intracardiac echocardiography (ICE) with the advantages of 2‐dimensional ICE and imaging capabilities of transesophageal echocardiography. The purpose of this study is to evaluate the real‐world, multicenter safety and performance of a novel 3‐dimensional ICE system in a variety of cardiac interventions used in standard clinical practice. Methods: This prospective, multicenter, observational, single‐arm study enrolled patients who were scheduled for an invasive cardiac procedure involving guidance with ICE and followed until discharge or ≤48 hours postprocedure. Intracardiac imaging was performed with the 3‐dimensional ICE catheter, VeriSight Pro (Philips Inc.). Fluoroscopy was used in all cases and transesophageal echocardiography was used in some cases. The primary safety end point was device‐related adverse events. The primary efficacy end point included technical success, imaging success, and clinical success. Results: Between October 2021 and November 2022, 155 patients were enrolled and screened. Percutaneous interventions performed included atrial septal defect/patent foramen ovale closures, left atrial appendage occlusion, catheter ablations, and valve procedures. No adverse events were related to the device or procedure. The technical, imaging, and clinical success rates were 98.7% (95% CI, 95.4%–99.8%), 96.1% (95% CI, 91.8%–98.6%), 94.8% (95% CI, 91.8%–98.6%), respectively. Overall, the VeriSight Pro ICE image quality was assessed to be “acceptable” or greater in relation to reference image modality among 96.2% (149 of 155) of procedures. Conclusions: VeriSight ICE imaging is safe and effective in the guidance of a wide variety of percutaneous cardiovascular procedures and has provided successful and high‐quality imaging of cardiac structures.